Profit before tax was at Rs 114.62 crore in the fourth quarter of FY25, up 19.70% from Rs 95.75 crore posted in the same period a year ago.
Total expenses increased 8.61% to Rs 447.55 crore in Q4 FY25, compared to Rs 412.05 crore reported in Q4 FY24. The cost of material consumed stood at Rs 185.45 crore (down 7.97% YoY), employee benefit expenses were at Rs 43.37 crore (up 43.37% YoY) and finance costs stood at Rs 6.58 crore (up 40.59% YoY) during the period under review.
On a full-year basis, the company’s net profit rose 25.58% to Rs 272.40 crore on a 14.16% increase in revenue to Rs 2,115.07 crore in FY25 over FY24.
The company's board has recommended a dividend of Rs 2.5 per equity share for the financial year 2024-25. Subject to the approval of the shareholders at the ensuing annual general meeting of the company.
Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India.
The counter declined 1.33% to Rs 757.15 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."